Print

HVTN 060

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine With or Without IL-12 DNA Adjuvant, Boosted With Homologous Plasmids or With HIV CTL Multiepitope Peptide Vaccine/RC529-SE Plus GM-CSF, in Healthy, HIV-1 Uninfected Adult Participants

Trial Details:

I Completed
Profectus BioSciences, National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network (HVTN) August 01, 2005
HIV-1 gag DNA Gag B
HIV-1 gag DNA DNA
IL-12 DNA adjuvant
Thailand, USA 144
NCT00111605
http://www.clinicaltrials.gov/ct/show/NCT00111605?order=1